High blood pressure may pose greatest risk of death in MASLD
High blood pressure is a leading cardiometabolic risk factor — a condition linked to problems such as heart disease, stroke, and diabetes — associated with…
Lila Levinson, PhD, Science Writer—
Articles by Lila Levinson, PhD
7 genes identified as potential biliary atresia treatment targets
Researchers identified seven genes that may contribute to biliary atresia, a discovery that could provide opportunities to develop treatments or biological markers for the…
Roche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
Hormone-like therapy NF-1 shows promise in ICP mouse study
Nesfatin-1 (NF-1), a hormone-like molecule that may ease cellular stress, reduced injury to the placenta in a mouse model of intrahepatic cholestasis of pregnancy…
New Alagille syndrome therapy named ART4 gets FDA designations
The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental therapy for Alagille syndrome…
New medications show promise for children with rare liver disease
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…
Targeting mitochondrial problems eases cholestasis in mouse model
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
Drug for fatty liver disease MASH may help prevent transplants
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
Chemomab, FDA align on key aspects of nebokitug development
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
Maternal liver damage markers can predict twin pregnancy outcomes
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…